Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: analysts and calls -- Goldman Sachs

No earlier versions found for this Subject.

Return to analysts and calls -- Goldman Sachs

RESEARCH ALERT-NPS Pharmaceuticals started as 'outperform'
Friday September 27, 12:00 pm ET

NEW YORK, Sept 27 (Reuters) - Goldman Sachs said on Friday it started coverage of NPS Pharmaceuticals Inc. (NasdaqNM:NPSP - News) with a "market outperformer" rating, citing the sales potential from its products, strong partnerships and stock price valuation.

Goldman said in a research note it assigned the rating based on the momentum of two of the company's Phase III products, its broad scientific platform and other factors.

But the brokerage said a projected lack of profitability until 2007 could raise the volatility of NPS shares. The shares closed at $20.18 on Thursday on Nasdaq.